No news or media exposure can be detected.
It is an extremely large jump relative to other stocks that have made it on our watch list. However, such interest in a stock in one day, with no news, warrants attention.
Insite Vision develops and markets ophthalmic pharmaceutical products, including AzaSite, which is indicated for the treatment of bacterial conjunctivitis.
On August 28, the company announced that the FDA accepted its NDA for AzaSite for review.
Friday's action could be a sign of an FDA decision in the near future.